论文部分内容阅读
郭夏,加拿大多伦多大学药物学硕士英国哈瑞—瓦特大学MBA,美国药物学家协会会员,加拿大药物科学家协会会员在北美著名跨国制药企业和研究机构工作10年,曾任加拿大万全药业首席执行官1998年6月回国,创办万全科技药业有限公司,任总裁兼首席执行官。2005年5月获第二届《北京市留学人员创业奖》。万全科技药业有限公司(以下简称万全)的迅猛崛起,引起了世界的关注。创业几年来,其销售收入和利润的复合增长率分别高达133%和383%,这惊人的业绩更令国内外金融界瞩目。2002年,万全被美国《财富》杂志中文版和中国著名的金融杂志《数字财富》分别评为“中国个具有惊人潜力的企业之一”和“最具有潜力成为中国未来前10名的大型企业的公司”。
Guo Xia, Master of Pharmacology, University of Toronto, Canada MBA, member of American Institute of Pharmacologists and member of Canadian Association of Pharmaceutical Scientists 10 years working as a leading transnational pharmaceutical company and research institute in North America, former Chief Executive of Wanquan Pharmaceutical Jun returned to China in June 1998, founded Wan Quan Technology Pharmaceutical Co., Ltd., president and chief executive officer. May 2005 won the second “Beijing Overseas Students Entrepreneurship Award.” Wanquan Technology Pharmaceutical Co., Ltd. (hereinafter referred to Wanquan) the rapid rise has aroused the world’s attention. In the past few years, the compound annual growth rate of its sales revenue and profit were as high as 133% and 383% respectively. This amazing performance has drawn more attention from the financial circles at home and abroad. In 2002, Wan Quan was rated as “one of China’s enterprises with tremendous potential” by the Chinese version of Fortune Magazine and “Digital Fortune”, a well-known financial magazine in China, and “one of the most promising enterprises in China to become the top 10 in the future.” s company".